ORMP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	240 759
Average Volume	171 829
Market Cap	89.14M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $0.0200 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	15.71
ATR14	$0.0110 (0.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Reznick Yehuda	Buy	29 800	Common Stock
2024-04-01	Reznick Yehuda	Buy	0
2024-01-30	Aghion Daniel	Buy	3 750	Common Stock
2024-01-04	Kidron Miriam	Buy	295 500	Common Stock
2024-01-04	Kidron Nadav	Buy	329 000	Common Stock

INSIDER POWER
92.83
Last 95 transactions
Buy: 3 987 636 \| Sell: 392 701

Volume Correlation

Long: -0.07 (neutral)

Short: -0.19 (neutral)

Signal:(56.796) Neutral

Oramed Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oramed Pharmaceuticals Correlation - Currency/Commodity

-0.39
( neutral )

-0.43
( neutral )

0.00
( neutral )

0.54
( weak )

-0.25
( neutral )

0.49
( neutral )

Oramed Pharmaceuticals Financials

Annual	2022
Revenue:	$2.70M
Gross Profit:	$2.70M (100.00 %)
EPS:	$-0.970

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0797

Q2	2023
Revenue:	$674 000
Gross Profit:	$674 000 (100.00 %)
EPS:	$-0.0297

Q1	2023
Revenue:	$666 000
Gross Profit:	$666 000 (100.00 %)
EPS:	$-0.0449

Financial Reports:

No articles found.

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.